- Home
- MOD vs MRNA Comparison
MOD vs MRNA Comparison
Compare MOD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOD | MRNA |
|---|---|---|
| Founded | 1916 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MOD | MRNA |
|---|---|---|
| Price | $216.50 | $42.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 11 |
| Target Price | ★ $202.60 | $30.80 |
| AVG Volume (30 Days) | 1.7M | ★ 13.5M |
| Earning Date | 02-04-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $2,873,900,000.00 | $1,944,000,000.00 |
| Revenue This Year | $19.06 | $5.45 |
| Revenue Next Year | $17.95 | $14.54 |
| P/E Ratio | $118.19 | ★ N/A |
| Revenue Growth | ★ 13.15 | N/A |
| 52 Week Low | $64.79 | $22.28 |
| 52 Week High | $235.02 | $55.20 |
Technical Indicators
Market Signals| Indicator | MOD | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 80.64 | 54.21 |
| Support Level | $213.49 | $36.66 |
| Resistance Level | $235.02 | $45.50 |
| Average True Range (ATR) | 13.10 | 3.14 |
| MACD | 3.39 | -0.86 |
| Stochastic Oscillator | 80.66 | 38.86 |
Price Performance
Historical ComparisonAbout MOD Modine Manufacturing Company
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.